Windlas Biotech Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 3 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.0K Cr

Windlas Biotech has outperformed the industry in the last 11 quarters despite low overall volume growth in the Indian Pharma Market (IPM). Windlas Biotech refrains from providing explicit forward-looking guidance on growth or profits.

From Windlas Biotech Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹994

Market Cap

₹2.0K Cr

P/E Ratio

29.5

How does Windlas Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Compare Windlas Biotech Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Windlas Biotech Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹16 Cr.

Full financials →

📊 Revenue & Sales Performance

→Windlas Biotech has outperformed the industry in the last 11 quarters despite low overall volume growth in the Indian Pharma Market (IPM).
→Future growth drivers include:
→ - Expanding as a strong, quality-recognized player in contract manufacturing and Trade Generics.
→ - Dosage form expansion, notably into injectables.
→ - Expected rebound in suppressed volume growth due to increasing patient base, hospital beds, and income levels in India.
→The company refrains from giving exact forward-looking growth guidance but is optimistic about continued growth driven by quality, execution, and product portfolio expansion.
→Organic growth focused on oral solids with plans for inorganic expansion for other dosage forms.
→Growth potential in exports exists, with ongoing efforts to expand the business development team and pursue acquisitions to accelerate scaling.
→Operating leverage and ramp-up of new facilities, such as the injectable plant, are expected to contribute to margin improvement and growth over the next 2-3 years.

📈 Profitability & Margins

→Windlas Biotech refrains from providing explicit forward-looking guidance on growth or profits.
→The company has delivered 11 consecutive quarters of growth, outperforming the Indian Pharmaceutical Market (IPM) with low volume growth.
→Growth drivers include:
→ - Strong quality and regulatory compliance positioning.
→ - Dosage form expansion, notably into injectables.
→ - Expected latent volume growth in the Indian market due to favorable demographics and increased healthcare access.
→EBITDA margins are improving; Q2 FY '26 EBITDA margin excluding ESOP impact was 13.5%.
→The company targets a 15% EBITDA margin but hasn’t provided a definitive timeline.
→Operating leverage from the new injectable facility is expected to support margin improvement over the next 2-3 years.
→ESOP-related non-cash expenses will dampen profit growth in the short term but are viewed as a long-term investment in talent and execution.
→Overall margin improvement is expected, dependent on execution and growth.

See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Plant-6 expansion is advancing well and is on track to commission within FY '26.
→Continued investments in quality, compliance, and capability expansion across dosage forms.
→Focus on organic growth via Plant-2 extension and Plant-6 for oral solids.
→Open to inorganic expansion to broaden portfolio, especially for new dosage forms, seeking good non-sick assets even at a premium.
→Investment in people emphasized through ESOP schemes to align talent with strategic growth.
→Possible future acquisition considered to bolster the Exports vertical and dosage form capabilities.
→Intent to pick up and build additional dosage form in-house if no external asset is found by injectable facility's near-peak capacity utilization.

💰 Fundraising & Capital Structure

→No explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company has a strong liquidity position with INR237 crores and healthy net operating cash flow of INR56 crores as of H1 FY '26.
→Focus appears on organic growth, operational efficiency, and potential inorganic acquisition but no clear guidance on raising funds via debt or equity.
→The management discussed investments primarily through internal accruals and organic expansions like Plant-6 and injectable facility expansions.
→There is an indication of being open to acquisitions, which may involve capital, but no specific mention of needing external fundraising for that purpose.

See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The transcript does not explicitly provide specific details on the current or expected order book or pending orders for Windlas Biotech Limited. However, some relevant insights related to orders and business progress include: - Injectable facility: Commercialized several products; regular orders are now being received with increasing customer confidence (Page 10). - New dosage forms and products are gradually being added as customers gain experience with the manufacturing plant. - The company is actively expanding its customer base and product portfolio across three verticals, indicating ongoing and future order growth (Page 13). - Efforts are being made to increase exports and ramp up the trade generics segment, signaling potential order growth (Pages 7-8). - No direct quantitative data on order book size or pending orders is disclosed in the transcript. Thus, while qualitative updates suggest growing and recurring orders, no specific numbers on order book or pending orders are provided.

Key Metrics

What Windlas Biotech's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
Solara Active (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
Sun Pharma.Inds. (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Windlas Biotech Ltd Q2 FY26 results?

What is Windlas Biotech Ltd share price analysis?

Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.

Is Windlas Biotech Ltd planning capital expenditure?

Plant-6 expansion is advancing well and is on track to commission within FY '26.

Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.